|
9th Annual Conference of the British HIV Association24 – 26 April 2003, University of Manchester |
| Oral Abstracts | |
| O1 | AIDS-FREE SURVIVAL OF 218 HIV-INFECTED WOMEN FOLLOWING PREGNANCY BHIVA Conf 2003 Apr 24-26;9:O1 GP Taylor1, L Sarner2, W Khan3, L Navaratne4, D Mercey5, EGH Lyall6, A Fakoya2, D Hawkins3 and A de Ruiter4 These data demonstrate good maternal health for up to 4 years following the management of HIV infection in pregnancy.  Download Abstract Book 2003
|
| O2 | SEMINAL SUPER-SHEDDING OF HIV: IMPLICATIONS FOR SEXUAL TRANSMISSION BHIVA Conf 2003 Apr 24-26;9:O2 S Taylor1,3, T Sadiq2, D White1, C Sabin2, P Cane1,3, S Drake1 and D Pillay2 12% of this cohort were SSS as defined by the reversed SP:BP ratio. We postulate that within these individuals viral replication is occurring locally within the genital tract. Furthermore, when virus is produced at a high concentrations, these individuals may have a high probability of transmitting HIV during sexual acts. Download Abstract Book 2003
|
| O3 | SPERM WASHING IN THE UK: EVIDENCE OF SAFETY AND EFFICACY BHIVA Conf 2003 Apr 24-26;9:O3 C Gilling-Smith, B Tamberlin, A Cox, G Rozis, JR Smith, S Barton and PA Almeida Sperm washing in a specialist centre is safe and effective as a risk-reduction treatment. Lack of NHS funding for this service may force couples to consider unprotected intercourse. Health Authorities must address this issue. Download Abstract Book 2003
|
| O4 | AN ESTIMATION OF THE UK DEMAND FOR FERTILITY SERVICES IN HIV-POSITIVE COUPLES BHIVA Conf 2003 Apr 24-26;9:O4 LCG Frodsham, F Boag, S Barton and C Gilling-Smith The demand for fertility services in HIV-infected couples is high. Our survey reinforces the need to improve current services to meet the demand and improve the information available to referring physicians. Download Abstract Book 2003
|
| O5 | NEUROLOGICAL AND DEVELOPMENTAL OUTCOMES IN HIV-INFECTED CHILDREN PRESENTING BEFORE 3 YEARS OF AGE BHIVA Conf 2003 Apr 24-26;9:O5 EGH Lyall, C Foster, D Melvin and R Biggs Severe early HIV disease is related to abnormal neurology with motor impairment and developmental delays. Our results emphasise the need for regular developmental monitoring and have implications for community services. Download Abstract Book 2003
|
| O6 | MIGRATION AND HIV: IMPACT ON SERVICE DELIVERY BHIVA Conf 2003 Apr 24-26;9:O6 C Chapman and J Dhar Migrants dispersed to our area have contributed significantly to our cohort of HIV-positive individuals. A large number of these females are presenting with advanced disease and require HAART, either for themselves or to prevent vertical transmission. As this dispersal continues, more clinics will need to develop patient care pathways, with access to both healthcare and social-care professionals. Download Abstract Book 2003
|
| O7 | DURABILITY OF EFAVIRENZ COMPARED TO NEVIRAPINE WITH LONG-TERM FOLLOW-UP OF AN ANTIRETROVIRAL-NAÏVE PATIENT COHORT BHIVA Conf 2003 Apr 24-26;9:O7 G Matthews, Y Gilleece, C Orkin, S Mandalia, MR Nelson, B Fisher, M Bower and BG Gazzard This cohort provides the strongest evidence yet that durability of EFV over NVP continues with long-term follow-up. Download Abstract Book 2003
|
| O8 | THE SUCCESS OF TENOFOVIR (TNF) AND DIDANOSINE (DDI) WHEN DOSED TOGETHER USING LOW-DOSE DIDANOSINE 250 MG BHIVA Conf 2003 Apr 24-26;9:O8 M Tung, A Pathmanathan, J Chandra, M Bower, BG Gazzard and MR Nelson Our clinical cohort has shown that TNF with ddI at 250 mg compares favourably with ddI at 400 mg. Thus low-dose ddI at 250 mg plus TNF is an effective combination. Download Abstract Book 2003
|
| O9 | EFAVIRENZ: WHAT HAPPENS IN THE LONG-TERM? BHIVA Conf 2003 Apr 24-26;9:O9 L Swaden, CA Sabin, FC Lampe, MS Youle, MA Johnson and M Lipman EFV is a potent drug, though there is a high incidence of discontinuation due to AEs. These occur at a much later time (years rather than weeks) than reported previously. Download Abstract Book 2003
|
| O10 | OPTIMISING OUTCOMES TO ANTIRETROVIRAL THERAPY: A COMPREHENSIVE MULTIDISCIPLINARY APPROACH BHIVA Conf 2003 Apr 24-26;9:O10 HA Leake Date1, CA Sabin2 , D Churchill1, G Dean1, D Williams1 and M Fisher1 VL suppression rates (<50 copies/ml) of >90% can be achieved in routine clinical practice by the adoption of a structured multidisciplinary approach. Download Abstract Book 2003
|
| O11 | DOSE ESCALATION OR IMMEDIATE FULL DOSE WHEN SWITCHING FROM EFAVIRENZ- TO NEVIRAPINE-BASED HAART? BHIVA Conf 2003 Apr 24-26;9:O11 A Winston, A Pozniak, N Smith, C Fletcher, S Mandalia, D Parmar, S Gibbons, D Back, BG Gazzard and MR Nelson When changing from EFV to NVP, patients should start on 200 mg bd initially, for therapeutic plasma drug levels without increased toxicity. Although virological failure was seen in those given lowerdose NVP, subtherapeutic plasma levels occurred for 3 weeks, which has potential for the development of drug-resistant virus. Download Abstract Book 2003
|
| O12 | IMPACT OF ARCHIVED NRTI RESISTANCE MUTATIONS ON MAINTENANCE OF VIROLOGICAL CONTROL AFTER SWITCHING FROM STAVUDINE TO TENOFOVIR WITH AN UNDETECTABLE VIRAL LOAD BHIVA Conf 2003 Apr 24-26;9:O12 C McDonald1, S Kegg2, R Kulasegaram3, M Smith1, C Taylor1, P Easterbrook1, B Peters3, P Hay2 and AM Geretti1 In NRTI-experienced patients switching from stavudine to tenofovir with a PI-based regimen, virological control was maintained despite a history of resistance mutations known to affect tenofovir. Download Abstract Book 2003
|
| O13 | CDE CHEMOTHERAPY PLUS HAART FOR AIDS-RELATED NON-HODGKIN'S LYMPHOMA BHIVA Conf 2003 Apr 24-26;9:O13 C Thirlwell, J Stebbing, MR Nelson, BG Gazzard and M Bower Treatment with CDE and HAART is associated with a median survival of over 1 year, comparing favourably with our previous regimens. The OS correlated with NHL-related factors (IPI index) rather than HIV-associated factors (CD4 count and viral load). This differs from prognostic indicators of the pre-HAART era. Download Abstract Book 2003
|
| O14 | PEGYLATED INTERFERON (PIFN) AND RIBAVIRIN (RBV) IN THE TREATMENT OF ACUTE HEPATITIS C IN INDIVIDUALS CO-INFECTED WITH HIV BHIVA Conf 2003 Apr 24-26;9:O14 Y Gilleece, C Orkin, R Browne, D Asboe, BG Gazzard and MR Nelson Treatment of acute HCV results in higher rates of PCR negativity with no loss of HIV virological control. Tolerability of PIFN and RBV is problematic and our data suggest that shorter courses of HCV treatment should be assessed for efficacy. Download Abstract Book 2003
|
| O15 | CO-INFECTION WITH HIV-1 AND HEPATITIS C DOES NOT ABLATE THE ALLOSTIMULATORY FUNCTION OF DENDRITIC CELLS BHIVA Conf 2003 Apr 24-26;9:O15 S Portsmouth, J Stebbing, MR Nelson, S Patterson, FM Gotch and BG Gazzard Monocyte-derived DCs from HIV-1 and HCV co-infected individuals have a similar allostimulatory capacity to DCs from patients with HIV-1. This has implications for immunotherapeutic approaches in co-infected individuals and is consistent with recent data showing that HCV and HIV-1 do not negatively affect one another. Download Abstract Book 2003
|
| O16 | INCREASING INCIDENCE OF ACUTE HEPATITIS C IN HIV POSITIVE MEN SECONDARY TO SEXUAL TRANSMISSION: A NEW EPIDEMIC? BHIVA Conf 2003 Apr 24-26;9:O16 RE Browne, D Asboe, YC Gilleece, MC Atkins, S Mandalia, BG Gazzard and MR Nelson The high number of individuals reporting unsafe sex, low documented IDU and a high rate of concomitant syphilis infection suggests that sexual transmission is fuelling a significant increase in HCV seroconversion. Download Abstract Book 2003
|
| O17 | OUTCOME OF ACUTE HEPATITIS C IN HIV-POSITIVE HOMOSEXUAL MEN BHIVA Conf 2003 Apr 24-26;9:O17 RM Lascar1, A Smith2, S Smith2, E Macfarlane1 and RJC Gilson1,2 Some patients clear HCV RNA spontaneously after acute infection, but in this small series, reactivation occurred in all cases. Interferon treatment is feasible; however, larger prospective studies are needed, including study of the long-term outcome. Download Abstract Book 2003
|
| O18 | SURVIVAL IN HIV-INFECTED INDIVIDUALS FOLLOWING LIVER TRANSPLANTATION IS INFLUENCED BY VIRAL CO-INFECTION: THE NEGATIVE IMPACT OF HCV INFECTION BHIVA Conf 2003 Apr 24-26;9:O18 S Norris, C Taylor, C McDonald, J O'Grady, BC Portmann, AS Knisely, M Bowles, P Muiesan, M Rela and N Heaton The long-term outcome of LT in HIV-infected patients with HBV or other causes of chronic liver disease indicates that this is an acceptable therapeutic option for these patients. However, the long-term prognosis for HCV-HIV co-infected patients must remain guarded. Download Abstract Book 2003
|
| O19 | GROWTH HORMONE AND EFFECTIVE ANTIRETROVIRAL THERAPY AUGMENT IMMUNE FUNCTION OF HIV-1 INFECTED INDIVIDUALS BHIVA Conf 2003 Apr 24-26;9:O19 A Pires, J Pido-Lopez, GJ Moyle2, BG Gazzard2, FM Gotch1 and N Imami1 Concomitant administration of rhGH at 4 mg/day with HAART appears to attenuate the defects exerted on the immune system by HIV-1. This combination may be a valuable immunotherapeutic intervention for chronic HIV-1 infection. Download Abstract Book 2003
|
| O20 | THE HEAT SHOCK PROTEIN RECEPTOR CD91 IS UP-REGULATED IN MONOCYTES OF HIV-1-INFECTED 'TRUE' LONG TERM NON-PROGRESSORS BHIVA Conf 2003 Apr 24-26;9:O20 J Stebbing1, S Portsmouth1, A Wildfire1, FM Gotch1, MR Nelson1, M Bower1, S Shaunak1, P Srivastava2, BG Gazzard1 and S Patterson1 High levels of CD91 may be a host factor that contributes to maintenance of long-term non-progression. Its ability to internalise α-defensins and cross-present exogenous antigen to cytotoxic T lymphocytes via major histocompatibility class I may maintain CD8+ responses in these individuals. Download Abstract Book 2003
|
| O21 | THE IMPACT OF ANTIRETROVIRAL THERAPY AND/OR IMMUNOTHERAPY ON THE LEVELS OF CIRCULATING β-CHEMOKINES AND IL-16 IN HIV-1 INFECTED INDIVIDUALS BHIVA Conf 2003 Apr 24-26;9:O21 CT Burton1, GAD Hardy1, AK Sullivan2, MR Nelson2, BG Gazzard2, FM Gotch1 and N Imami1 Immunotherapy had little effect on plasma levels of MIP-1β. Patients treated with NNRTI-based HAART show a significantly higher level of MIP-1α and MIP-1β. These higher levels may be beneficial, as high levels of β-chemokines have been associated with slower disease progression. Download Abstract Book 2003
|
| O22 | ATORVASTATIN AND PRAVASTATIN FOR HYPERCHOLESTEROLAEMIA IN HIV-POSITIVE PATIENTS RECEIVING HAART BHIVA Conf 2003 Apr 24-26;9:O22 NP Smith, MR Nelson, GJ Moyle and BG Gazzard Both A and P decrease serum cholesterol in HIV-positive patients receiving HAART. Patients receiving A were significantly more likely to have a decrease in cholesterol to <6.6 mmol/l compared with those receiving P. We recommend that A be considered as first-line ahead of P for the treatment of hypercholesterolaemia in HIV-positive patients receiving HAART. There was no clear difference in the effect on protease inhibitor (PI)-containing regimens compared with non-PI regimens between treatment groups. Download Abstract Book 2003
|
| O23 | EXOCRINE PANCREATIC INSUFFICIENCY IN HIV-POSITIVE PATIENTS BHIVA Conf 2003 Apr 24-26;9:O23 DA Price, KMB Ajdukiewicz, B Peaston, ELC Ong, MH Snow and ML Schmid HIV+ patients with chronic diarrhoea on HAART should have their pancreatic function assessed, particularly if associated with weight loss or symptoms of fat malabsorption and, if deficient, should be treated with pancreatic enzyme supplements. Download Abstract Book 2003
|
| O24 | CHANGING MORTALITY PATTERNS IN THE HAART ERA BHIVA Conf 2003 Apr 24-26;9:O24 J Ashby1, AK Sullivan1, V Kugananthan1, C Watson1, C Mazude1, M Fisher2, M Bower1, BG Gazzard1 and MR Nelson1 Mortality has decreased with the advent of HAART. At the time of death individuals have a higher CD4 cell count and are less likely to have had a previous AIDS diagnosis. The spectrum of causation is changing with higher rates due to AIDS-defining cancers, systemic lymphomas, and liver disease and self-harm, while the proportion of deaths from Kaposi's sarcoma (KS) and primary cerebral lymphoma (PCL) has fallen. Download Abstract Book 2003
|
| O25 | IS IT TIME TO RETHINK THE ROLES OF HEALTH PROFESSIONALS IN THE HIV OUTPATIENT SETTING? BHIVA Conf 2003 Apr 24-26;9:O25 S Dave1, K Miles1,2, DE Mercy2, C Griffiths2 and SG Edwards1 A high proportion of patients attending routine HIV outpatient clinics have needs that could be met by other healthcare professionals. With an ever-increasing demand on services, there is a need to develop cost-effective models of care that match the patient caseload with appropriate professional expertise without reducing the quality of care. Download Abstract Book 2003
|
| O26 | MISSED OPPORTUNITIES TO DIAGNOSE HIV INFECTION BHIVA Conf 2003 Apr 24-26;9:O26 L Adejolu, S Ash and W Lynn Clinicians still fail to recognise HIV-related symptoms, resulting in unnecessary morbidity and mortality. There is a continuing need to raise HIV awareness, particularly in areas of high local prevalence. Download Abstract Book 2003
|
| O27 | NATIONAL STRATEGY DOES NOT ENSURE PCT-LEVEL PRIORITY OR NATIONAL EQUITY FOR HIV SERVICES BHIVA Conf 2003 Apr 24-26;9:O27 L Power, D Pinson, J Kinniburgh and M Kirk Simultaneous introduction of the National Strategy alongside NHS reorganisation has had a damaging effect upon coordination and prioritisation of HIV services and has failed, so far, to improve national access or tackle the rising rates of sexual ill-health and HIV. Download Abstract Book 2003
|
| O28 | CD4 CELL COUNTS IN HIV-INFECTED ADULTS AT HIV DIAGNOSIS IN ENGLAND AND WALES, 1990 TO 2001 BHIVA Conf 2003 Apr 24-26;9:O28 T Chadborn, S Dingley, D Morgan, BG Evans Many adults are still diagnosed with CD4 levels at which the initiation of HAART is associated with reduced survival. Monitoring CD4 counts will help to assess the goals of the Sexual Health Strategy. Download Abstract Book 2003
|
| O29 | SOUTH ASIANS WITH HIV INFECTION IN LONDON: A GROWING EPIDEMIC? BHIVA Conf 2003 Apr 24-26;9:O29 G Sethi1, E Fox2, IG Williams3, CA Sabin3, CJ Lacey1, A Shaw4 and M Kapembwa4 In order to respond appropriately to the evolving epidemic among SAs, it is critical to understand the socio-cultural differences that may lead to non-attendance at GUM clinics and late presentation. Download Abstract Book 2003
|
| O30 | HIV AND BLACK CARIBBEANS IN THE UK BHIVA Conf 2003 Apr 24-26;9:O30 Dougan S, Payne L, Fenton K, Evans B New HIV diagnoses among black Caribbeans in the UK are increasing, against a background of a high incidence of bacterial sexually transmitted infections in this community. Targeted and culturally sensitive prevention methods are required to address this issue. Download Abstract Book 2003
|
| Poster Abstracts | |
| P1 | THE IMPACT OF NRTI RESISTANCE MUTATIONS ON RESPONSES TO TENOFOVIR AS PART OF SALVAGE THERAPY IN AN ETHNICALLY DIVERSE POPULATION OF DRUG-EXPERIENCED PATIENTS IN SOUTH LONDON BHIVA Conf 2003 Apr 24-26;9:P1 C McDonald1, R Kulasegaram2, M Smith1, S Kegg3, C Taylor1, P Easterbrook1, B Peters2, P Hay3 and AM Geretti1 Among highly treatment-experienced patients with NRTI resistance mutations known to affect tenofovir susceptibility, 44% showed a sustained virological response to salvage therapy containing tenofovir and 53% a significant immunological response. Download Abstract Book 2003
|
| P2 | AUDIT OF ADHERENCE TO BHIVA RESISTANCE TESTING GUIDELINES BHIVA Conf 2003 Apr 24-26;9:P2 BM Holden, N Mackie, J Clarke, J Walsh, L Greene and J Weber The use of resistance testing at St Mary's closely follows the BHIVA recommendations. The development of a local protocol will help ensure good practice continues. Download Abstract Book 2003
|
| P3 | FACTORS INFLUENCING NEVIRAPINE PLASMA CONCENTRATIONS BHIVA Conf 2003 Apr 24-26;9:P3 SE Gibbons1, L Almond1, H Reynolds1, L Dickinson1, L Robinson1, SH Khoo1, M Boffito1,2, S Bonora2, G Di Perri2 and DJ Back1 These data highlight some of the potential factors influencing NVP plasma concentrations. Download Abstract Book 2003
|
| P4 | THE UK HIV DRUG RESISTANCE DATABASE BHIVA Conf 2003 Apr 24-26;9:P4 D Dunn, R Matthias and T Hill on behalf of the UK Collaborative The UK HIV Drug Resistance Database is a rich resource that will enable: (1) insights into HIV drug resistance in vivo; (2) analysis of use/impact of resistance testing in clinical management; (3) surveillance for transmitted and secondary drug resistance; and (4) feedback of electronic data to participating centres for local analyses and audit. Download Abstract Book 2003
|
| P5 | LOPINAVIR/RITONAVIR COMBINED WITH INDINAVIR AT 400 MG TWICE A DAY: PHARMACOKINETICS AND PHARMACODYNAMICS IN BLOOD, CEREBROSPINAL FLUID (CSF) AND SEMEN BHIVA Conf 2003 Apr 24-26;9:P5 A Isaac1, S Taylor1,2, E Smit1, P Cane1,2, S Gibbons3, D White1, S Drake1 and D Back3 IDV did not significantly alter median LPV PK parameters. IDV in BP (Cmin), CSF and semen was >IC90 for wild-type in most samples. Download Abstract Book 2003
|
| P6 | PHENOTYPIC CHANGES INDUCED BY ANTIRETROVIRAL THERAPY INTERVENTION DURING RECENT HIV-1 INFECTION BHIVA Conf 2003 Apr 24-26;9:P6 A Pires, A Pozniak, MR Nelson, BG Gazzard, FM Gotch and N Imami Initiation of ART during recent infection significantly reduces T-cell activation and induces effector CD8+CD45RA+CD27- T-cell formation. CD4+ and CD8+ T-cell numbers appeared to change towards values closer to normality. Download Abstract Book 2003
|
| P7 | SURVEILLANCE OF HIV DRUG RESISTANCE IN THE UK: A SENTINEL SITE STUDY BHIVA Conf 2003 Apr 24-26;9:P7 P Scott1, E Arnold2, B Evans3, GJ Moyle3, A Pozniak3, M Shahmanesh4, D White5, J Shirley1, P Cane1 and D Pillay1 This is the first such sentinel surveillance dataset from the UK and is relevant to the increased transmission of HIV drug resistance observed over this period. Download Abstract Book 2003
|
| P8 | THE PREVALENCE OF THE K65R MUTATION IN HIV-1 REVERSE TRANSCRIPTASE IN PATIENTS RECEIVING TENOFOVIR BHIVA Conf 2003 Apr 24-26;9:P8 A Winston, A Pozniak, BG Gazzard and MR Nelson The prevalence of K65R is unchanged with the advent of the use of tenofovir over a 2-year period. However, the specific combination of abacavir/didanosine/tenofovir was associated with a high prevalence of K65R, which may be due to all components of this regimen selecting for the development of this mutation. Download Abstract Book 2003
|
| P9 | THE IMPACT OF REDUCING DIDANOSINE DOSAGE FROM 400 MG TO 250 MG WHEN COMBINED WITH TENOFOVIR BHIVA Conf 2003 Apr 24-26;9:P9 MS Youle, L Swaden, K Smith, J Ballinger, A Mackleworth, CA Sabin, C Smith and MA Johnson Although a minority of patients experienced increases in the viral load after a reduction in ddI dose, many of these were known to have taken treatment breaks at the time. In the other patients, a reduction in the ddI dose from 400 to 250 mg did not appear to have a detrimental effect on virological control. Download Abstract Book 2003
|
| P10 | THE PREVALENCE OF HYPOPHOSPHATAEMIA IN PATIENTS TAKING TENOFOVIR BHIVA Conf 2003 Apr 24-26;9:P10 HA Leake Date, A Bannister and M Fisher The excellent short-term tolerability of TDF has resulted in its widespread use, but as with all new agents, vigilance is required to identify longer-term and/or infrequent toxicities. While there appears to be a significant minority of TDF recipients who develop HP, the clinical value of routine monitoring of SP and urinalysis requires further evaluation. Download Abstract Book 2003
|
| P11 | THE ASSOCIATION BETWEEN NEVIRAPINE AND ABNORMAL LIVER FUNCTION TESTS IN A COHORT SETTING BHIVA Conf 2003 Apr 24-26;9:P11 GV Matthews, Y Gilleece, C Orkin, S Mandalia, G Salomov, MR Nelson and BG Gazzard Despite a high incidence (18%) of patients on NVP with an ALT >100 IU/ml or 2.5× baseline, only 29% of these were directly related to NVP and led to drug cessation. Most abnormal transaminases on NVP (71%) were due to other causes or were isolated readings. Download Abstract Book 2003
|
| P12 | GOUT AND HIV: A NEW FACET OF THE FAT REDISTRIBUTION SYNDROME? BHIVA Conf 2003 Apr 24-26;9:P12 S Creighton1, GP Kasidas2, SG Edwards and P French1 We report a high level of gout in our HIV population from 2000 onwards, especially in patients receiving boosted protease inhibitors. Most of these patients had dyslipidaemia and clinical features of lipodystrophy. As gout is known to be associated with insulin resistance, atherosclerosis and visceral fat accumulation in the HIV-negative population, this suggests that gout may be another metabolic complication of HAART. Download Abstract Book 2003
|
| P13 | AUDIT OF ADHERENCE SERVICES PROVIDED BY A SPECIALIST HIV CLINIC BHIVA Conf 2003 Apr 24-26;9:P13 G Chana, D Godfrey and M Rodgers Although the BHIVA/MSSVD guidelines have not made any quantitative recommendations, adherence raised in 22% of cases would be considered low. Doctors were less likely to record or measure adherence than the pharmacist. The development of local adherence guidelines using a standardised tool for measuring and documenting adherence would further improve this. Download Abstract Book 2003
|
| P14 | CLINICAL RELEVANCE OF A PROGRAMME TO SUSTAIN ADHERENCE BHIVA Conf 2003 Apr 24-26;9:P14 GC Orofino1, P Leombruni2, L Lavagnino2, M Bolgiani2, S Carosella1 and P Caramello1 This intervention to improve and sustain adherence in non-adherent patients may achieve a clinical benefit through a reduction in the viral load, which would probably be even more evident with a longer follow-up. Download Abstract Book 2003
|
| P15 | CHANGES IN SYMPTOM EXPERIENCE AND INTERPRETATION OVER TIME: EFFECTS ON ADHERENCE BHIVA Conf 2003 Apr 24-26;9:P15 V Cooper1, G Gellaitry1, M Fisher2 and R Horne1 These findings have implications for the continued monitoring of symptoms attributed to HIV and aggressive treatment of HAART side effects to ensure that adherence is optimised and maintained over time. Download Abstract Book 2003
|
| P16 | WHAT IS THE FUTURE OF HIV PREVENTION? BHIVA Conf 2003 Apr 24-26;9:P16 S McLean1 and R Webb2 Through examining the nine essential feature of effective HIV prevention, gaps in the UK response will be identified, and an advocacy agenda for the future of HIV prevention in the UK will be proposed. Download Abstract Book 2003
|
| P17 | HIV-1 INFECTION AMONG BLACK CARIBBEANS IN SOUTHEAST LONDON BHIVA Conf 2003 Apr 24-26;9:P17 I Aggarwal1, M Smith1, AM Geretti1, ID Tatt2, JV Parry2, S Murad1 and PJ Easterbrook1 Non-B subtypes were common among our population. In-depth studies to gain insights into the emerging HIV epidemic among black Caribbeans in the UK are urgently needed. Download Abstract Book 2003
|
| P18 | HIV RESOURCE USE IN SECONDARY CARE: A MODEL DESIGNED TO SUPPORT NHS RESOURCE PLANNING BHIVA Conf 2003 Apr 24-26;9:P18 S Mendes da Costa1, D Godfrey2 and C Avila1 The model was most useful in areas with limited data sources or rapid population growth. It can be used as a tool to identify resources required for current and future populations. Download Abstract Book 2003
|
| P19 | EMERGING PATTERNS OF HIV TRANSMISSION ASSOCIATED WITH EXPERIENCES OF TORTURE AND TRAUMA IN AFRICAN WOMEN IN EAST LONDON BHIVA Conf 2003 Apr 24-26;9:P19 J Miah, M Poulton, J Lewis and M Payet Clinical management of patients presenting with high levels of distress (where the underlying factors are unclear) presents challenges and can impact on care provided, not only in terms of the process of engagement with the medical care system, but also with regard to adherence, disclosure, sexual and mental health. Download Abstract Book 2003
|
| P20 | RISK BEHAVIOUR AND THE MEANING OF 'RESISTANCE' IN A SAMPLE OF HIV POSITIVE AFRICANS ACCESSING SERVICES IN CENTRAL LONDON: CLINICIANS BE AWARE BHIVA Conf 2003 Apr 24-26;9:P20 O Davidson, M. Chinouya, L Ndawula and M Sesay This sample of HIV-positive African migrants report significant levels of risk behaviour and misinformation regarding HIV and 'resistance'. Clinicians and other service providers must take care when discussing 'resistance' with these patients. Download Abstract Book 2003
|
| P21 | BRIDGING THE GAP BETWEEN PAEDIATRIC AND ADULT HIV SERVICES BHIVA Conf 2003 Apr 24-26;9:P21 K Miles1,2, K Prime1, J Sudlow1, E Kirkpatrick1, M Clapson3, N Penny1 and SG Edwards1 This study supports the need for effective transition policies and the development of adolescent-specific models of care that facilitate continuity between paediatric and adult services. Download Abstract Book 2003
|
| P22 | HIV PREVALENCE IN PREGNANT WOMEN IN NORTH THAMES: 1998–2001 BHIVA Conf 2003 Apr 24-26;9:P22 MC Borja1, S Cliffe1,2, P Tookey1, D Williams1, WD Cubitt1 and C Peckham1 There was no significant rise in HIV prevalence in women born outside SSA. Over 90% of children at risk of vertical transmission of HIV had at least one parent born abroad. Download Abstract Book 2003
|
| P23 | UPTAKE OF HIV TESTING IN PATIENTS WITH A CONFIRMED SEXUALLY TRANSMITTED INFECTION BHIVA Conf 2003 Apr 24-26;9:P23 SL Day, K Chee, C Rodgers and D Lakhani The clinic interventions increased HIV testing in patients attending the genitourinary clinic, including those confirmed with an STI. These figures are in keeping with sexual health strategy targets. Download Abstract Book 2003
|
| P24 | SEXUAL FUNCTIONING IN HIV+ WOMEN BHIVA Conf 2003 Apr 24-26;9:P24 S Lambert, A Keegan and J Petrak Sexual difficulties, including abstinence, were prevalent in this sample, indicating the potential for interventions addressing the psychosexual needs of HIV+ women and their partners. Download Abstract Book 2003
|
| P25 | IMPROVING SEXUAL HEALTH CARE ACCESS IN THE HIV OUTPATIENT SETTING: A MULTIPRACTITIONER APPROACH BHIVA Conf 2003 Apr 24-26;9:P25 K Miles1,2, D Grover1, B George1, SG Edwards1 Offering a multitiered sexual health service within HIV outpatient clinic allows a high level of patient access, retains essential sexual health skills for all staff and distributes the ever-increasing workload among all practitioners. Download Abstract Book 2003
|
| P26 | INCREASING SYPHILIS SURVEILLANCE IN AN HIV CLINIC IN RESPONSE TO THE CURRENT OUTBREAK IN MANCHESTER BHIVA Conf 2003 Apr 24-26;9:P26 SK Vitharana1, MA Kingston1, EGL Wilkins1, SP Higgins1 and P Tilson2 The introduction of routine STSs to the HIV clinics has resulted in the new diagnosis of a significant number of syphilis infections and has proved a worthwhile intervention. The increased uptake of STSs from the current 45% would result in the detection of additional cases and we recommend that patients with syphilis should be referred to GUM for further management. Download Abstract Book 2003
|
| P27 | SEX AND RELATIONSHIPS FOR HIV+ WOMEN BHIVA Conf 2003 Apr 24-26;9:P27 A Keegan, S Lambert and J Petrak Women are experiencing a range of sexual and relationship difficulties that appear to be relatively unchanged despite the advent of HAART. Focused psychosexual and couples work should be more readily available for HIV+ women and their partners. Download Abstract Book 2003
|
| P28 | COST OF HIV TREATMENT AND CD4 COUNTS IN UK ANTIRETROVIRAL-NAÏVE HIV-INFECTED PATIENTS ON HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART), 1996–2000 BHIVA Conf 2003 Apr 24-26;9:P28 S Mandalia1, D Parmar1, G Baily2, R Brettle2, M Fisher2, M Gompels2, G Kinghorn2, B McCarron2, E Ong2, A Pozniak2, A Tang2, MS Youle1, BG Gazzard1 and EJ Beck1 on behalf of the NPMS-HHC Steering Group Strong linear relationship were observed between the CD4 count and treatment costs. For those staying on first-line therapy, annual costs decreased. These data can be used to assess drug costefficacy or to assess resource requirements for new or existing services. Download Abstract Book 2003
|
| P29 | HIV/AIDS RELATED KNOWLEDGE, ATTITUDE AND PRACTICE AMONG HIGH SCHOOL STUDENTS IN EASTERN NEPAL BHIVA Conf 2003 Apr 24-26;9:P29 M Lakhey This education programme brought about statistically significant positive changes in the knowledge of and attitudes to (16 of 27 questions tested) HIV/ADIS. There was a great sense of unwillingness to discuss information about sexual practices (31% response). 2.4% had had sexual intercourse. Download Abstract Book 2003
|
| P30 | ABACAVIR HYPERSENSITIVITY IN HIV-POSITIVE PATIENTS: DEMONSTRATION OF THE PRESENCE OF DRUG-SPECIFIC LYMPHOCYTE PROLIFERATION IN VITRO BHIVA Conf 2003 Apr 24-26;9:P30 FJ Vilar1,2, CC Dodd2, DJ Naisbitt2, SF Gordon2, JL Maggs2, SH Khoo2, BK Park2 and M Pirmohamed2 PBMCs from a subset of ABC-hypersensitive patients proliferated following in vitro drug antigen stimulation. This provides the first direct laboratory evidence that ABC hypersensitivity is T-cell mediated. The support of GSK is acknowledged. Download Abstract Book 2003
|
| P31 | DELAYED-TYPE IMMUNE RESTORATION DISEASE (IRD) AFTER EFFECTIVE ANTIRETROVIRAL THERAPY (ART) IS ASSOCIATED WITH LACK OF SPECIFIC T-CELL RESPONSES BHIVA Conf 2003 Apr 24-26;9:P31 A Pires1, MR Nelson1, A Pozniak1, M Fisher2, BG Gazzard1, FM Gotch1 and N Imami1 IRD is associated with inadequate immune reconstitution rather than a vigorous specific T-cell response. Furthermore, concomitant administration of immunotherapy with effective ART may be associated with a more rapid immune recovery. Download Abstract Book 2003
|
| P32 | INITIATION OF ANTIRETROVIRAL THERAPY (ART) DURING RECENT HIV-1 INFECTION RESULTS IN LOWER RESIDUAL VIRAL RESERVOIRS AND WEAK HIV-1 SPECIFIC RESPONSES BHIVA Conf 2003 Apr 24-26;9:P32 A Pires, G Hardy, S Portsmouth, BG Gazzard, FM Gotch and N Imami A reduction of HIV-1 pDNA to levels comparable to those seen in LTNPs is only apparent if therapy is initiated during the early stages of disease. The timing appears to be more sensitive for preserving HIV-1-specific T-cell responses. Download Abstract Book 2003
|
| P33 | EFFECT OF INTERLEUKIN (IL)-2 THERAPY ON T-CELL PHENOTYPE, ACTIVATION AND IL-2 RECEPTOR EXPRESSION BHIVA Conf 2003 Apr 24-26;9:P33 AK Sullivan1, G Hardy2, C Burton2, A Pires2, M Nelson1, F Gotch2, BG Gazzard1 and N Imami2 These data support the current approach to IL-2 therapy, with a prolonged lag between IL-2 induction and maintenance therapy. Download Abstract Book 2003
|
| P34 | KAPOSI'S SARCOMA (KS)-SPECIFIC DENDRITIC CELLS (DCS) RESPOND TO KS-ASSOCIATED ANTIGENS THROUGH CD91, THE HEAT-SHOCK PROTEIN (HSP) RECEPTOR BHIVA Conf 2003 Apr 24-26;9:P34 J Stebbing, S Portsmouth, U Kim, F Gotch, MR Nelson, M Bower, S Patterson and BG Gazzard Infected and functionally impaired DCs can cross prime immune responses via CD91. These results have important implications for the aetiopathogenesis of KS and for the development and design of any compounds including antitumour and antiviral vaccines that are derived from cellular lysates. Download Abstract Book 2003
|
| P35 | LIMITED THYMIC CONTRIBUTION TO INITIAL CD4 T-CELL RESTORATION DURING SUPPLEMENTATION OF HAART WITH INTERLEUKIN (IL)-2 AND/OR REMUNE BHIVA Conf 2003 Apr 24-26;9:P35 J Pido-Lopez, C Burton, G Hardy, A Pires, R Aspinall, BG Gazzard, F Gotch and N Imami Despite early increases in CD4 in the first 20 weeks of therapy in patients given IL-2, TREC levels declined. These results indicate little thymic contribution to CD4 restoration and suggest proliferation and/or redistribution as the mechanism responsible for CD4 rises as well as the TREC decline. Increases in CD4 and total T-cell numbers accompanied by rises in TRECs beginning at week 50 suggests a late contribution by the thymus to cell restoration. Download Abstract Book 2003
|
| P36 | EVALUATION OF INTERFERON (IFN)-γ T-CELL RESPONSES DURING ANTIRETROVIRAL THERAPY (ART) IN COMPARISON WITH THOSE OF LONG-TERM NON-PROGRESSORS (LTNPS) BHIVA Conf 2003 Apr 24-26;9:P36 G Hardy1, N Imami1, M Gartland2, C Van Wely2, MR Nelson1, N Qazi1, BG Gazzard1, E D'Souza2 and FM Gotch1 LTNPs make high IFN-γ responses to HIV-1 peptides and antigens. In contrast, ART-treated patients with undetectable viral loads demonstrate disparate IFN-γ T-cell responses. When viraemia is positive, the magnitude of response appears to relate to that of the CD4 count. Download Abstract Book 2003
|
| P37 | REDUCED INTERFERON (IFN)-γ PRODUCTION IN HAART TREATED HIV-1+ INDIVIDUALS: PARTIAL RECOVERY ON GROWTH HORMONE THERAPY BHIVA Conf 2003 Apr 24-26;9:P37 MR Goodier1, N Imami1, GJ Moyle2, L Rennalls1, BG Gazzard2 and FM Gotch1 NK cells from HAART-treated subjects may be defective in common pathways leading to IFN-γ production. Human growth hormone therapy results in partial recovery of NK-cell function. Download Abstract Book 2003
|
| P38 | DEVELOPMENT OF AUTOLOGOUS NEUTRALISING ANTIBODIES FOLLOWING PRIMARY HIV INFECTION BHIVA Conf 2003 Apr 24-26;9:P38 MMI Aasa Chapman1, A Hayman2, D Cornforth3, P Newton3, IG Williams3, P Balfe2 and A McKnight1 We conclude that the presence of NAbs alone does not play a major role in determining the viral load set-point after PHI. Download Abstract Book 2003
|
| P39 | RECENT HIV INFECTIONS IN HETEROSEXUALS: IS STARHS APPLICABLE? BHIVA Conf 2003 Apr 24-26;9:P39 G Murphy, I Tatt, N Osner, K Barlow, J Clewley, LF Jordan, ON Gill and JV Parry These results indicate continuing transmission of HIV in heterosexuals. Although an annual incidence cannot be calculated, the measurement of proportions of recent infection among those infected with non-B subtypes provides a means of monitoring current transmission patterns. Download Abstract Book 2003
|
| P40 | HIV INCIDENCE REMAINS CONSTANT IN MEN WHO HAVE SEX WITH MEN (MSM) DESPITE WIDESPREAD USE OF EFFECTIVE ANTIRETROVIRAL THERAPY BHIVA Conf 2003 Apr 24-26;9:P40 G Murphy, A Charlett, LF Jordan, N Osner, ON Gill and JV Parry Despite the increasingly effective use of antiretroviral therapy, we found no evidence of a significant decline in HIV incidence. Individuals whose HIV infection has been diagnosed should be less infectious, but 22% of infections in MSM remain undiagnosed, many with acute STIs, and this may be an important driver of the ongoing epidemic. Initiatives to diagnose and treat a greater proportion of HIV infections, including those with a suspected seroconversion illness, may be key to reducing the HIV incidence in MSM. Download Abstract Book 2003
|
| P41 | DEATHS IN SEROCONVERTERS WITHOUT AIDS SINCE THE INTRODUCTION OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART) IN THE UK BHIVA Conf 2003 Apr 24-26;9:P41 T Power and K Porter for the UK Register of HIV Seroconverters The role of hepatitis infection and non-AIDS-defining cancers as causes of death merits further research, particularly given the high CD4 levels at which deaths occur. Download Abstract Book 2003
|
| P42 | POST-EXPOSURE PROPHYLAXIS (PEP) FOR HIV AFTER SEXUAL EXPOSURE: SOUTH THAMES HIV PHYSICIANS SURVEY BHIVA Conf 2003 Apr 24-26;9:P42 T Newell, EF Fox and P Bunting The majority of physicians in South Thames were willing to prescribe PEPSI after high-risk sexual exposure to HIV but there was a wide variation in willingness to prescribe PEPSI in lower-risk situations or when the HIV status of the partner was unknown. In the absence of specific UK guidelines on sexual exposure, the majority would prescribe drugs recommended in 2000 by the UK Department of Health for occupational exposure to HIV. This questionnaire highlights the need for UK guidelines on PEPSI to guide management of these cases. Download Abstract Book 2003
|
| P43 | GENDER DIFFERENCE IN HIV VIRAL LOAD LEVELS: NORTH AMERICAN AND EUROPEAN WOMEN HAVE CONSISTENTLY LOWER VIRAL LOADS BHIVA Conf 2003 Apr 24-26;9:P43 CA Donnelly1, AC Ghani1, AM Le Fevre1, LM Bartley1, Frank de Wolf1,2 and RM Anderson1 Given antiretroviral treatment decisions may depend on the viral load, the finding that differences between men and women are consistent in different countries should provide a solid scientific basis for the development of gender-specific treatment guidelines, if appropriate. Download Abstract Book 2003
|
| P44 | GENDER DIFFERENCES IN THE RATE OF STOPPING HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART) BHIVA Conf 2003 Apr 24-26;9:P44 S Shah, C Smith, FC Lampe, MS Youle, MA Johnson, AN Phillips and CA Sabin Median times to stopping/switching a first HAART regimen were quite long. Rates of stopping may be higher in women. Download Abstract Book 2003
|
| P45 | ACUTE HEPATITIS C (HCV) IN A COHORT OF HIV-POSITIVE HOMOSEXUAL MEN: PATIENT CHARACTERISTICS, RISK FACTORS AND OUTCOMES BHIVA Conf 2003 Apr 24-26;9:P45 K Aizen, S Fletcher, S. Bhagani, G Dusheiko and MA Johnson Unprotected anal intercourse, fisting, oral sex and a recent history of a STD were identified as sexual risk factors. We continue to monitor outcome to therapy. Download Abstract Book 2003
|
| P46 | PREVALENCE OF HEPATITIS C (HCV) IN AN ETHNICALLY DIVERSE HIV INFECTED COHORT IN SOUTH LONDON BHIVA Conf 2003 Apr 24-26;9:P46 AH Mohsen, AM Geretti, S Murad and P Easterbrook A moderate prevalence of HCV infection was observed in our HIV-1-infected cohort. This is likely to be much higher in cohorts with a greater representation of injecting drug users. Download Abstract Book 2003
|
| P47 | PNEUMONIA DUE TO ANTIBIOTIC-RESISTANT STREPTOCOCCUS PNEUMONIAE (SP) AND PSEUDOMONAS AERUGINOSA (PA) IS ASSOCIATED WITH ADVANCED HIV INFECTION IN INDIVIDUALS RECEIVING HIGHLY ACTIVE ANTIRETROVIRAL THERAPY BHIVA Conf 2003 Apr 24-26;9:P47 SH Allen1, P Brennan-Benson1, J Stebbing2, D Asboe2, B Azadian1, BG Gazzard2 and MR Nelson1,2 These findings have implications for the treatment of patients with serious infections given blind antibiotic treatment. Download Abstract Book 2003
|
| P48 | PARADOXICAL REACTIONS IN TB PATIENTS WITH AND WITHOUT HIV CO-INFECTION BHIVA Conf 2003 Apr 24-26;9:P48 RAM Breen, H Bettinson, CJ Smith, S Dart, B Bannister, MA Johnson and MCI Lipman Our data confirm that a PR is common in HIV/TB patients but is related to several distinct clinical scenarios. Download Abstract Book 2003
|
| P49 | OCCULT HEPATITIS B VIRUS INFECTION IN HIV-INFECTED PATIENTS BHIVA Conf 2003 Apr 24-26;9:P49 A Bonington1, E Bodey2 and A Bailey3 Occult HBV infection does occur in HIV-infected patients but does not seem to be related to the level of immunosuppression. It is hypothesised that this reflects HBV reactivation in this sample population. The significance of occult HBV in HIV-infected subjects remains uncertain and further study is required. Download Abstract Book 2003
|
| P50 | CHEMO-IRRADIATION FOR ANAL SQUAMOUS CELL CARCINOMA IN THE ERA OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART) BHIVA Conf 2003 Apr 24-26;9:P50 A Hanna-Morris1, S Stewart2, M Fisher3, C Cottrill4, D Boote5, C Collis6, TG Allen-Mersh1, M Bower1 The toxicity and treatment outcome of chemo-irradiation for anal SCC in patients with concomitant HAART is similar to that of the non-HIV population. The stoma-sparing justification for chemoirradiation applies to these patients. Download Abstract Book 2003
|
| P51 | INCIDENCE AND OUTCOME OF HIV-RELATED LUNG CANCER IN THE ERA OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART) BHIVA Conf 2003 Apr 24-26;9:P51 T Powles, MR Nelson, S Mandalia, S Cox, P Shah, BG Gazzard and M Bower In this study, HL occurred more frequently in the post- HAART era compared with the general population. The outcome of this disease may have improved since the introduction of HAART. Download Abstract Book 2003
|
| P52 | NATURAL HISTORY OF HIGH-GRADE ANAL INTRAEPITHELIAL NEOPLASIA (HGAIN) IN HIV-POSITIVE HOMOSEXUAL MEN BHIVA Conf 2003 Apr 24-26;9:P52 HB Lacey1, DM Butterworth1 and D Rana2 The rate of progression to Ca is low over 5 years, but malignant change may take longer. Regression is not a rare event. Cytology is a specific but relatively insensitive tool to screen for HGAIN. More data about the progression rate and the evaluation of effective treatments are needed before the introduction of screening. Download Abstract Book 2003
|
| P53 | ANGIOGENIC CORRELATES IN THE TREATMENT OF AIDS-RELATED KAPOSI'S SARCOMA (KS) BHIVA Conf 2003 Apr 24-26;9:P53 J Stebbing, S Portsmouth, T Powles, C Thirlwell, MR Nelson, BG Gazzard and M Bower Angiogenic cytokines may correlate with KS disease extent. The response to paclitaxel therapy was correlated with a fall in plasma IL-6 levels, and data suggest that this correlates with KS herpesvirus viral load. The overall clinical response in KS was correlated poorly with known angiogenic cytokines. Download Abstract Book 2003
|
| P54 | HISTOPATHOLOGICAL CORRELATES IN KAPOSI'S SARCOMA (KS) BHIVA Conf 2003 Apr 24-26;9:P54 A Lafuente, N Francis, C Thirlwell, MR Nelson, BG Gazzard and M Bower Although the nodular subtype of KS is associated with visceral involvement, it is not correlated with lower CD4 cell counts. This suggests that factors other than host-cell-mediated immunity (e.g. inflammatory cytokines in the tumour microenvironment and human herpesvirus-8 strain variants) are associated with visceral dissemination of KS. Download Abstract Book 2003
|
| P55 | A STUDY COMPARING DISEASE CHARACTERISTICS AND TREATMENT OUTCOMES IN HIV-POSITIVE AND HIV-NEGATIVE POPULATIONS WITH ANAL HUMAN PAPILLOMAVIRUS (HPV) DISEASE ATTENDING AN ANOSCOPY CLINIC BHIVA Conf 2003 Apr 24-26;9:P55 S Rackstraw and M Nathan The presentation characteristics of anal HPV disease were similar in both the HIV+ and HIV– cohorts. Cure rates from anal HPV disease were similar in both HIV+ and HIV– cohorts. No significant differences were noted in disease presentation or cure rates in either cohort. Download Abstract Book 2003
|
| P56 | KAPOSI'S SARCOMA (KS) IN THE THIRD MILLENNIUM BHIVA Conf 2003 Apr 24-26;9:P56 A Lafuente, C Thirlwell, J Stebbing, MR Nelson, BG Gazzard, M Bower The majority of patients who present with KS in the third millennium are either HAART-naïve or are failing HAART therapy. The mortality associated with KS is low, and even when visceral disease is present, this is not an adverse prognostic variable for survival. The high frequency of fatal Castleman's disease in this cohort reflects the well-known association with human herpesvirus-8 and the lack of effective therapies for HIV-associated Castleman's disease. Download Abstract Book 2003
|
| P57 | FACTORS ASSOCIATED WITH VIROLOGICAL REBOUND IN THOSE WHO INITIALLY CONTROL VIRAEMIA WITH ANTIRETROVIRAL THERAPY (ART) BHIVA Conf 2003 Apr 24-26;9:P57 CJ Smith, AN Phillips, FC Lampe, S Shah, MS Youle, MA Johnson and CA Sabin The change in CD4 count from the time of virological suppression could be used to predict when virological failure is likely to occur. Further information can be gained from the current CD8 count. Switching or adding a PI, an NNRTI or ABC increases the risk of virological failure and may be related to the reasons why patients switch. Download Abstract Book 2003
|
| P58 | FIRST-LINE HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART) EXPERIENCES AT THE ROYAL FREE HOSPITAL BHIVA Conf 2003 Apr 24-26;9:P58 CJ Smith, S Shah, FC Lampe, MS Youle, MA Johnson, AN Phillips and CA Sabin Both patients and clinicians must evaluate likely toxicities as well as clinical efficacy when deciding on first-line HAART. Download Abstract Book 2003
|
| P59 | RELATIONSHIP BETWEEN HIV-1 VIRAL SUBTYPE, DISEASE PROGRESSION AND RESPONSE TO ANTIRETROVIRAL THERAPY BHIVA Conf 2003 Apr 24-26;9:P59 PJ Easterbrook1, M Smith1, J Mullen2, S O'Shea2, AM Geretti1, S Murad1, I Chrystie2, AM de Ruiter2, M Mvere1, B Kulasegaram2, M Zuckerman1 for the Guy's, King's and St Thomas's HIV Virology Collaborative Group 86.5% of non-B subtypes identified on EIA were confirmed on env sequencing. Analyses were based on 867 patients with complete data. 457 were B, and 317 were non-B subtype, of which 60 (19%) were A, 114 (36%) were C, 30 (9%) were D and 14 (4.4%) were infected with recombinant strains: the most common was CRF02_AG (n=8). Most (85.2%) non-B and recombinant strains were in black Africans from sub-Saharan Africa (mostly Uganda, Zimbabwe, Nigeria, Ivory Coast and Ghana). There was a similar rate of pretreatment CD4 decline and similar time to viral undetectability for B, A, C and D subtypes. Download Abstract Book 2003
|
| P60 | EXPOSURE TO ANTIRETROVIRAL THERAPY (ART) AND ITS RELATIONSHIP TO VIROLOGICAL STATUS: RESULTS FROM THE UK CHIC STUDY BHIVA Conf 2003 Apr 24-26;9:P60 CA Sabin and T Hill for the UK Collaborative HIV Cohort (CHIC) Steering Committee This patient population has become increasingly treatment-experienced over time. While those exposed to all three classes of drugs show little evidence of failing treatment, a number of them do have detectable viral loads, highlighting the urgent need to develop new classes of drugs and drugs with limited cross-resistance. Download Abstract Book 2003
|
| P61 | TRIZIVIR AND TENOFOVIR AS A SIMPLE SALVAGE REGIMEN BHIVA Conf 2003 Apr 24-26;9:P61 V Latham, BG Gazzard, M Bower and M Nelson Salvage therapy with Trizivir/tenofovir is associated with an improved outcome in heavily pretreated patients with a resistance history of less than three TAMs. Compliance is still a problem. Download Abstract Book 2003
|
| P62 | FACTORS ASSOCIATED WITH LONG-TERM CD4 CELL RISES AMONG THOSE RECEIVING HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART) BHIVA Conf 2003 Apr 24-26;9:P62 CJ Smith, AN Phillips, FC Lampe, S Shah, MS Youle, MA Johnson and CA Sabin These findings emphasise the importance of maintaining virological suppression, and suggest other factors that also influence the long-term CD4 cell response. Download Abstract Book 2003
|
This information is designed to support, not replace, the relationship that exists between you and your doctor.
©1980, 2003. AEGiS.